Drug Profile
Research programme: transforming growth factor-beta1 inhibitor - Digna Biotech
Alternative Names: NAFB002; NAFB002 P17; P 17Latest Information Update: 09 Jan 2017
Price :
$50
*
At a glance
- Originator Digna Biotech
- Class Peptides
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Bone metastases; Corneal ulcer; Dry eyes; Fibrosis; Malignant melanoma
Most Recent Events
- 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Spain (Ophthalmic)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone metastases in Spain (Intraperitoneal)